下剤薬がうつ病関連の記憶・注意障害を改善する可能性を発見 (Laxative Could Treat Depression-Related Memory Issues)

ad

2026-06-12 バーミンガム大学

英国のUniversity of BirminghamとUniversity of Oxfordの研究チームは、慢性便秘治療薬として承認されているプルカロプリド(Prucalopride)が、うつ病に伴う記憶力や注意力の低下を改善する可能性を示した。研究では、過去にうつ病エピソードを経験した50人を対象に、プルカロプリドまたはプラセボを7~10日間投与し、記憶力、注意力、実行機能などの認知機能を評価した。その結果、プルカロプリド投与群では短期・長期記憶や実行機能が有意に向上し、課題遂行の正確性と反応速度も改善した。プルカロプリドはセロトニン受容体(5-HT4受容体)を刺激する薬剤で、腸だけでなく脳にも作用することが知られている。研究者らは、うつ症状が改善した後も残存しやすい「ブレインフォグ」や認知機能障害に対し、新たな治療選択肢となる可能性があると指摘している。既に承認済み薬剤であることから臨床応用へのハードルも比較的低く、今後は大規模試験を通じて有効性や安全性の検証が進められる予定である。

<関連情報>

寛解期うつ病患者における5-HT4受容体作動薬の認知機能促進効果 Pro-cognitive effects of 5-HT4 receptor agonism in individuals with remitted depression

Angharad N. de Cates,Sorcha Hamilton,Anutra Guru,Merethe Blandhol,Michael Colwell,Philip J. Cowen,Meghan Simmons,Bailey Jones,Catherine J. Harmer and Susannah E. Murphy
Phycological Medicine  Published:15 June 2026
DOI:https://doi.org/10.1017/S0033291726104450

下剤薬がうつ病関連の記憶・注意障害を改善する可能性を発見 (Laxative Could Treat Depression-Related Memory Issues)

Abstract

Background

Cognitive impairment is a common and persistent feature of depression, yet it remains poorly understood and inadequately treated. Preclinical and human studies suggest that stimulating 5-HT4 receptors (5-HT4R) enhances neuroplasticity and improves cognition. This novel study examines the cognitive effects of 5-HT4R agonism in adults with a history of recurrent depression.

Methods

Fifty participants who were not currently depressed but had experienced at least two previous episodes of depression were randomized in a double-blind design either to prucalopride (2 mg daily, titrated from 1 mg) or to placebo for 7–10 days. Participants completed self-report questionnaires and a task battery at baseline and post-intervention assessing declarative memory, working memory, emotional processing, and executive function.

Results

Compared to placebo, prucalopride significantly improved word recall on an auditory verbal learning task and was associated with faster response times on a complex working memory task without loss of accuracy. It also improved the accurate recognition of rapidly presented facial expressions. Composite analysis of non-emotional tasks identified that the prucalopride group participants post-intervention were faster and more accurate than at baseline compared to those receiving placebo. Prucalopride had minimal effects on affective cognition, consistent with previous findings. Cognitive improvements were independent of baseline mood symptoms or self-reported cognitive difficulties.

Conclusions

Short-term 5-HT4R agonism improved performance on multiple objective cognitive measures in individuals with remitted depression. These findings replicate our previous results in healthy volunteers showing a pro-cognitive effect of prucalopride and support a role for 5-HT4Rs as a promising target for cognitive enhancement in mood disorders.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました